mercredi 1 mars 2017

Onco Actu du 1er mars 2017

2. Etiologie

Study Finds No Evidence Of Common Herpes Type Virus In Aggressive Brain Cancer Tissue [Johns Hopkins]

2.7 Etiologie - Obésité

Less than a stone of extra weight can boost cancer risk by half [The Telegraph]

Increased risk of 11 types of cancer linked to being overweight, researchers warn [The Guardian]

4. Dépistage, diagnostic et pronostic

Cell 'stickiness' could indicate cancer spread [BBC News]

4.10 Dép., diag. & prono. - Poumon

Nose swab detects tobacco damage linked to lung cancer in smokers [Cancer Research UK]

4.11 Dép., diag. & prono. - Ovaire

Screening with frequent personalized CA125 testing may improve detection of ovarian cancer in high-risk women [Mass. General Hospital]

4.7 Dép., diag. & prono. - Col de l'utérus

The Pap smear: groundbreaking, lifesaving — and obsolete? [STAT]

5.10 Traitements - Essais

Phase 3 Head-to-Head Trial Showed KYPROLIS® (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade® (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients [Amgen]

Longer survival seen with Amgen's Kyprolis vs Velcade in myeloma study [Reuters]

5.12.2 Immunothérapies - CAR-T

Positive Kite CAR-T data sees shares jump as it eyes FDA filing [FierceBiotech]

Kite scores a landmark win with promising 6-month lymphoma data for lead CAR-T [EndPoints]

Kite’s CAR-T cancer therapy shows strong results as company races to win FDA approval [STAT]

Kite Announces Positive Topline Primary Results of Axicabtagene Ciloleucel from First Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma [Kite]

Kite Pharma CAR-T Cancer Therapy Shows Strong, Durable Effect in Lymphoma Patients [The Street]

5.12.5 Immunothérapies - Pharma

Novartis cancer division races to catch up with rivals [Reuters]

5.2 Pharma

Nativis Lives the Life [In the Pipeline]

5.2.1 Pharma - Partenariats

Hitgen and Cancer Research UK’s Manchester Institute enter licence agreement in lung cancer [Cancer Research UK]

5.3.4 Traitements - AMM (FDA, EMA)

EMA Recommends Extensions of Indication for Daratumumab [ESMO]

5.4 Traitements - Economie

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [NICE]

UK rejects Merck's Keytruda as initial treatment for lung cancer [Reuters]

6. Lutte contre les cancers

The Future Of Precision Medicine: Great Promise, Significant Challenges [Health Affairs Blog]

6.1 Observation

Colorectal cancer mystery: Rising rates among millennials, Gen X [STAT]

Why Are More Young Americans Getting Colon Cancer? [NPR]

Study Finds Colorectal Cancer Rates Have Risen Dramatically in Gen X and Millennials [ACS]

What Do We Do Now That Colorectal Cancer Rates Are Increasing For Younger People? [Dr. Len]

Childhood cancer survivors benefit from reduced radiation treatment [Washington Post]

Colon and Rectal Cancers Rising in Young People [NY Times]

6.10.1 Politiques (USA)

Trump derides ‘slow and burdensome’ approval process at FDA [STAT]

Trump used a rare disease survivor to take a shot at the FDA [Vox]

Trump attacks “slow and burdensome” drug approval process in another blast crisping the FDA [EndPoints]

6.4 Médico-éco

Skin cancer from tanning beds costs US $343 million per year [STAT]

Breast cancer costs low-income women more jobs [Reuters]

6.7.1 Bioinformatique

How bioinformatics tools are bringing genetic analysis to the masses [Nature]

6.8 Communication

A Facebook-Style Shift in How Science Is Shared [NY Times]